Power3 Secures Exclusive License for Baylor s Proteomics Methods, Biomarkers

NEW YORK, July 20 (GenomeWeb News) - Power3 Medical Products said today that it has acquired exclusive worldwide licensing rights from Baylor College of Medicine for serum proteomics methods and biomarkers for the diagnosis of neurological disorders.

Power3 said that it co-developed the proteomics technology, which measures the concentration of proteins in the blood, in collaboration with Baylor researchers. The company said the biomarkers can be used to differentially diagnose a number of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS.

Under the terms of the agreement, the company has paid a licensing fee to Baylor, and will make additional payments upon reaching "certain developmental milestones." Power3 said it is responsible for continuing R&D costs for the technology, including the filing of patents.

Baylor is eligible for royalties on any product sales resulting from the commercialization of the technology, Power3 said.

Earlier this month, Power3 said it would soon begin clinical testing for a proteomics-based breast cancer test.